4SC Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
11
- Stock Symbol
-
VSC
- Investments
-
3
- Share Price
-
$0.12
- (As of Tuesday Closing)
4SC General Information
Description
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. The geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.
Contact Information
Website
www.4sc.comCorporate Office
- Fraunhoferstrasse 22
- 82152 Planegg-Martinsried
- Germany
Corporate Office
- Fraunhoferstrasse 22
- 82152 Planegg-Martinsried
- Germany
4SC Stock Performance
As of 16-Dec-2025, 4SC’s stock price is $0.12.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.12 | $0.15 | $0.10 - $6.56 | 13.2M | 6.42K | -$0.73 |
4SC Financials Summary
As of 31-Dec-2025, 4SC has a trailing 12-month revenue of $2.92M.
|
In Thousands, USD |
TTM 31-Dec-2025 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (4,840) | (4,840) | ||
| Revenue | 2,918 | 2,918 | 364 | 329 |
| EBITDA | (3,428) | (3,428) | (8,355) | (8,494) |
| Net Income | (3,922) | (3,922) | (9,018) | (8,913) |
| Total Assets | 9,187 | 9,187 | 9,222 | 10,394 |
| Total Debt | 0 | 0 | 0 | 0 |
4SC Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
4SC Patents
4SC Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2021064188-A1 | Combination comprising hdac inhibitor, ctla-4 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment | Inactive | 02-Oct-2019 | ||
| AU-2019254578-A1 | Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment | Inactive | 17-Apr-2018 | ||
| CA-3097087-A1 | Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment | Inactive | 17-Apr-2018 | ||
| EP-3781159-A1 | Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment | Inactive | 17-Apr-2018 | ||
| US-20230201161-A1 | Combination comprising hdac inhibitor, lag-3 inhibitor and a pd-1 inhibitor or pd-l1 inhibitor for cancer treatment | Inactive | 17-Apr-2018 | A61K31/40 |
4SC Signals
4SC Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
4SC Investments (3)
4SC’s most recent deal was a Seed Round with Panoptes Pharma for . The deal was made on 02-Nov-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Panoptes Pharma | 02-Nov-2015 | Seed Round | Drug Discovery | ||
| 8 Oncology Projects | 31-Jul-2008 | Corporate Asset Purchase | Buildings and Property | ||
| Nexigen | 26-May-2008 | Corporate | Drug Discovery |
4SC ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
4SC Exits (2)
4SC’s most recent exit was on 02-Nov-2015 from Panoptes Pharma. The exit was categorized as with 4 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Panoptes Pharma | 02-Nov-2015 | Completed |
|
||
| Nexigen | 26-May-2008 | Corporate | Completed |
4SC Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| 4SC Discovery | Munich, Germany | 1997 |
4SC FAQs
-
When was 4SC founded?
4SC was founded in 1997.
-
Where is 4SC headquartered?
4SC is headquartered in Planegg-Martinsried, Germany.
-
What is the size of 4SC?
4SC has 11 total employees.
-
What industry is 4SC in?
4SC’s primary industry is Drug Discovery.
-
Is 4SC a private or public company?
4SC is a Public company.
-
What is 4SC’s stock symbol?
The ticker symbol for 4SC is VSC.
-
What is the current stock price of 4SC?
As of 16-Dec-2025 the stock price of 4SC is $0.12.
-
What is 4SC’s current revenue?
The trailing twelve month revenue for 4SC is $2.92M.
-
What is 4SC’s annual earnings per share (EPS)?
4SC’s EPS for 12 months was -$0.73.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process